Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q8N743: Variant p.Gly231Asp

Killer cell immunoglobulin-like receptor 3DL3
Gene: KIR3DL3
Feedback?
Variant information Variant position: help 231 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Aspartate (D) at position 231 (G231D, p.Gly231Asp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (D) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help Various different KIR3DL3 alleles are known: KIR3DL3*00101, KIR3DL3*00102, KIR3DL3*00103, KIR3DL3*00201, KIR3DL3*00202, KIR3DL3*00203, KIR3DL3*00204, KIR3DL3*00205, KIR3DL3*00206, KIR3DL3*00207, KIR3DL3*0030101 KIR3DL3*0030102, KIR3DL3*00401, KIR3DL3*00402, KIR3DL3*005, KIR3DL3*00601, KIR3DL3*00602, KIR3DL3*007, KIR3DL3*00801, KIR3DL3*00802, KIR3DL3*00901, KIR3DL3*00902, KIR3DL3*010, KIR3DL3*01101, KIR3DL3*01102, KIR3DL3*012, KIR3DL3*01301, KIR3DL3*01302, KIR3DL3*01303, KIR3DL3*01304, KIR3DL3*01305, KIR3DL3*01306, KIR3DL3*01307, KIR3DL3*01401, KIR3DL3*01402, KIR3DL3*01403, KIR3DL3*01404, KIR3DL3*01405, KIR3DL3*015 KIR3DL3*016, KIR3DL3*017, KIR3DL3*018, KIR3DL3*019, KIR3DL3*020, KIR3DL3*021, KIR3DL3*022, KIR3DL3*023, KIR3DL3*024, KIR3DL3*025, KIR3DL3*026, KIR3DL3*027, KIR3DL3*028, KIR3DL3*029, KIR3DL3*030 and KIR3DL3*031. The sequence shown corresponds to the alleles KIR3DL3*002. Additional information on the polymorphism described.
Variant description: help In allele KIR3DL3*005. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 231 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 410 The length of the canonical sequence.
Location on the sequence: help DPLDIVVVGLYGKPSLSAQP G PTVQAGENVTLSCSSRSLFD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 26 – 410 Killer cell immunoglobulin-like receptor 3DL3
Topological domain 26 – 322 Extracellular
Glycosylation 239 – 239 N-linked (GlcNAc...) asparagine



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.